Trading Radar for 8/8: Nuance (NUAN), LendingClub (LC), Tyson Foods (TSN), Twilio (TWLO), Hertz (HTZ) Report

Jefferies Raises Price Target on Bellicum Pharma (BLCM) to $22; Reiterates Buy

Jefferies reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), and raised the price target to $22.00 (from $20.00), following the company's 2Q earnings report. BLCM reported a Q2 GAAP EPS of ($0.61) vs. estimates of ($0.59).

Analyst Biren Amin commented, "BLCM reported 2Q financial results... More

Leerink Partners Raises Price Target on ZELTIQ Aesthetics (ZLTQ) to $48; Reiterates Outperform

Leerink Partners reiterated an Outperform rating on ZELTIQ Aesthetics (NASDAQ: ZLTQ), and raised the price target to $48.00 (from $43.00), following the company's 2Q earnings report. ZLTQ reported revenues of $89.5M, ahead of the consensus' $80M estimate.

Analyst Richard Newitter commented, "ZLTQ remains a... More

Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q

Piper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following the company's 2Q earnings report. AGN reported non-GAAP diluted EPS of $3.35 on revenue of $3.68B, compared to Street estimates of $3.33 and $3.97B, respectively.

Analyst David Amsellem commented, "Allergan... More

Piper Jaffray Remains Sidelined on Endo Int'l (ENDP) Following 2Q Beat

Piper Jaffray reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and raised the price target to $19.00 (from $18.00), following the company's 2Q earnings report. ENDP reported non-GAAP diluted EPS of $0.86 on revenue of $921M, compared to Street estimates of $0.74 and $864M, respectively.

Analyst David Amsellem commented, "Endo reported 2Q16... More

Needham & Company Reiterates Buy on MaxLinear (MXL) Following 2Q Report

Needham & Company reiterated a Buy rating and $21.00 price target on MaxLinear (NYSE: MXL) following the company's 2Q earnings report. MXL reported 2Q16 revenue and NG EPS of $101.7MM/$0.50, vs. consensus' $102.0MM/$0.44 estimates. 3Q16 revenue is expected to be $94-98MM, well below $104MM estimates.... More

Piper Jaffray Remains Bullish on Nevro (NVRO) Following 2Q Beat and Raise

Piper Jaffray reiterated an Overweight rating on Nevro Corp (NYSE: NVRO), and raised the price target to $112.00 (from $98.00), following the company's 2Q earnings report. 2Q16 revenues were $55.4 million, primarily due to the ongoing launch of HF10 therapy in the United States. Full-year 2016 revenue guidance was... More

Needham & Company Reiterates Strong Buy on Inphi Corp. (IPHI) Following Solid 2Q

Needham & Company reiterated a Strong Buy rating on Inphi Corp. (NYSE: IPHI), and raised the price target to $45.00 (from $44.00), following the company's 2Q earnings report. IPHI reported revenue from continuing operations of $60.5MM, easily ahead of $57.5MM estimates. NG EPS was $0.32, including a $0.02 tax benefit,... More

RBC Capital Raises Estimates on Tyson Foods (TSN) Following 3Q; Reiterates Sector Perform

RBC Capital reiterated a Sector Perform rating on Tyson Foods (NYSE: TSN), and raised the price target to $75.00 (from $72.00), following the company's 3Q earnings report. RBC raised FY16 and FY17 EPS estimates from $4.38 and $4.79 to $4.56 and $4.96, both above consensus estimates.

Analyst David Palmer... More

FBR Capital Cuts Price Target on On Deck Capital (ONDK) to $6.00 Following 2Q

FBR Capital maintained a Market Perform rating on On Deck Capital (NYSE: ONDK), and cut the price target to $6.00 (from $6.50), following the company's 2Q earnings report. ONDK reported an operating loss of $0.20 per share, $0.04 above consensus. Lower marketing costs were the primary reason for the beat. The... More

Needham & Company Remains Sidelined on On Deck Capital (ONDK) Following 2Q

Needham & Company maintained a Hold rating on On Deck Capital (NYSE: ONDK) following the company's 2Q earnings report. 2Q revenue rose 10% Y/Y to $69.5M, above the consensus estimates of $67.8M. Management introduced 3Q revenue guidance of $73-76M compared to consensus' $74.8M.... More

Wedbush Cuts Price Target on National CineMedia (NCMI) Following Guide Down

Wedbush maintained an Outperform rating on National CineMedia (NASDAQ: NCMI), and cut the price target to $17.50 (from $19.00), as shares pull back. Management lowered 2016 guide to $440-450m (prior: $463-473m) in revenue and $220-230m (prior: $238-248m) in adjusted OIBDA.

Analyst... More

Oppenheimer Remains Bullish on Nuance Communications (NUAN) Following Mixed 3Q

Oppenheimer reiterated an Outperform rating and $26.00 price target on Nuance Communications (NASDAQ: NUAN) following the company's 3Q earnings report. NUAN reported revenues of $484.9M, slightly below the Streets $489.5M forecast due to a weak performance in the Healthcare segment. EPS of $0.38 rose 19.7%year-over-year, beating the... More

Needham & Company Raises Price Target on NeoPhotonics (NPTN) Following 2Q Results

Needham & Company reiterated a Strong Buy rating on NeoPhotonics (NYSE: NPTN), and raised the price target to $20.00 (from $18.00), following the company's 2Q earnings report. By CY4Q end, Neo should be producing roughly 75,000 iTLAs per quarter up from 28,000 in CY1Q. Needham increased revenue... More

Sina Corp (SINA) Tops Q2 EPS by 12c; Boosts FY16 Sales Outlook

Sina Corp (NASDAQ: SINA) reported Q2 EPS of $0.27, $0.12 better than the analyst estimate of $0.15. Revenue for the quarter came in at $244 million versus the consensus estimate of $231.69 million.

GUIDANCE:

Sina Corp sees FY2016 revenue of $950-1000 million, versus prior... More

Needham & Company Remains Bullish on ON Semiconductor (ON) Following 2Q

Needham & Company maintained a Buy rating and $14.00 price target on ON Semiconductor (NASDAQ: ON) following the company's 2Q earnings report. Revenue for the second quarter exceeded the high-end of guidance at $877.8 million, higher than expectations of $855 million. Non-GAAP EPS was reported at $0.23, inline with estimates.... More